Eureka Therapeutics, Inc.

Pei Wang

Cheng Liu

Su Yan

Jingyi Xiang

Wei Chan Tai

Nai-Kong V Cheung

Brian Wong

Hong Liu

Yiyang Xu

Emma Masteller

Ming Cheng

Hongfen Guo

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

Anti-ROR2 antibodies

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

Anti-ROR1 antibodies

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

Methods for generating host cells

Modified host cells and uses thereof

Modified glycoproteins and uses thereof

Growing community of inventors

Fremont, CA, United States of America

Pei Wang